| Autor: |
Ikegame S; Department of Microbiology at the Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA., Siddiquey MNA; Department of Microbiology and Immunology, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA., Hung CT; Department of Microbiology at the Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA., Haas G; Department of Microbiology at the Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA., Brambilla L; Department of Microbiology at the Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA., Oguntuyo KY; Department of Microbiology at the Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA., Kowdle S; Department of Microbiology at the Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA., Vilardo AE; National Administration of Laboratories and Health Institutes of Argentina (ANLIS) Dr. Carlos G. Malbrán, Buenos Aires, Argentina., Edelstein A; National Administration of Laboratories and Health Institutes of Argentina (ANLIS) Dr. Carlos G. Malbrán, Buenos Aires, Argentina., Perandones C; National Administration of Laboratories and Health Institutes of Argentina (ANLIS) Dr. Carlos G. Malbrán, Buenos Aires, Argentina., Kamil JP; Department of Microbiology and Immunology, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA., Lee B; Department of Microbiology at the Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. |
| Abstrakt: |
The novel pandemic betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected at least 120 million people since its identification as the cause of a December 2019 viral pneumonia outbreak in Wuhan, China1,2. Despite the unprecedented pace of vaccine development, with six vaccines already in use worldwide, the emergence of SARS-CoV-2 'variants of concern' (VOC) across diverse geographic locales have prompted re-evaluation of strategies to achieve universal vaccination3. All three officially designated VOC carry Spike (S) polymorphisms thought to enable escape from neutralizing antibodies elicited during initial waves of the pandemic4-8. Here, we characterize the biological consequences of the ensemble of S mutations present in VOC lineages B.1.1.7 (501Y.V1) and B.1.351 (501Y.V2). Using a replication-competent EGFP-reporter vesicular stomatitis virus (VSV) system, rcVSV-CoV2-S, which encodes S from SARS coronavirus 2 in place of VSV-G, and coupled with a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient S-mediated infection, we determined that only 1 out of 12 serum samples from a cohort of recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine showed effective neutralization (IC90) of rcVSV-CoV2-S: B.1.351 at full serum strength. The same set of sera efficiently neutralized S from B.1.1.7 and showed only moderately reduced activity against S carrying the E484K substitution alone. Taken together, our data suggest that control of some emergent SARS-CoV-2 variants may benefit from updated vaccines. |
